BME professor part of team that has published results of second large-scale study for tinnitus treatment

July 8, 2022 — An international team, including a University of Minnesota professor, has published a second large clinical trial for a novel neuromodulation device that could reduce symptoms for millions worldwide with tinnitus, commonly described as “ringing in the ears.” According to previous research, the condition is said to affect about 10-15 percent of the world’s population.

Researchers from Neuromod Devices Limited, the Irish medical device company specializing in the treatment of tinnitus, published the results of the company’s Treatment Evaluation of Neuromodulation for Tinnitus – Stage A2 (TENT-A2) clinical trial in the highly regarded scientific journal Nature – Scientific Reports.

University of Minnesota Professor Hubert Lim, in the Department of Biomedical Engineering (College of Science and Engineering) and the Department of Otolaryngology (Medical School) was the senior author of the study sponsored by Neuromod Devices. Lim also serves as chief scientific officer of Neuromod Devices.

Trial highlights

The TENT-A2 trial, which included 191 participants, is the company’s second large-scale clinical trial. TENT-A2 sought to replicate and further enhance the results demonstrated in the company’s TENT-A1 trial, a study with 326 participants that evaluated the safety and efficacy of Lenire, the company’s non-invasive bimodal neuromodulation approach that uses sound combined with electrical stimulation on the surface of the tongue to treat tinnitus.

Highlights of the TENT-A2 clinical trial results with Lenire treatment include:

  • At least 80 percent of participants experienced a reduction in their tinnitus symptoms after 12 weeks of treatment, as measured by the Tinnitus Handicap Inventory.
  • Treatment compliant participants achieved an average improvement in tinnitus symptoms of almost three times the clinically defined criterion.
  • 88 percent said they would recommend Lenire treatment to others with tinnitus.

Read the news release

Rendering of person wearing headphones with a device in their mouth
At least 80 percent of participants experienced a reduction in their tinnitus symptoms after 12 weeks of treatment.

Share